scholarly journals Treatment of spontaneous esophageal rupture (Boerhaave syndrome) using thoracoscopic surgery and sivelestat sodium hydrate

2018 ◽  
Vol 10 (4) ◽  
pp. 2206-2212 ◽  
Author(s):  
Hiroshi Okamoto ◽  
Ko Onodera ◽  
Rikiya Kamba ◽  
Yusuke Taniyama ◽  
Tadashi Sakurai ◽  
...  
Keyword(s):  
Thoracoscopic Surgery ◽  
Esophageal Rupture ◽  
Spontaneous Esophageal Rupture ◽  
Sivelestat Sodium Hydrate ◽  
Sodium Hydrate ◽  
Boerhaave Syndrome ◽  
Sivelestat Sodium

scholarly journals 977 Successful Endoscopic Closure of Spontaneous Esophageal Rupture (Boerhaave Syndrome)

2014 ◽  
Vol 79 (5) ◽  
pp. AB185
Author(s):  
Stijn J. Van Weyenberg ◽  
Fred J. Stam ◽  
Willem Marsman
Keyword(s):  
Esophageal Rupture ◽  
Spontaneous Esophageal Rupture ◽  
Endoscopic Closure ◽  
Boerhaave Syndrome

Abstract 122: Sivelestat Sodium Hydrate Treatment for Patients with Kawasaki Disease refractory to initial intravenous immunoglobulin therapy

Circulation ◽  
2015 ◽  
Vol 131 (suppl_2) ◽  
Author(s):  
Ryota Ebata ◽  
Kumi Yasukawa ◽  
Yuko Saito ◽  
Kouji Higashi ◽  
Nobuyuki Takada ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Laboratory Data ◽  
Total Duration ◽  
Ivig Therapy ◽  
University Hospital ◽  
Intravenous Immunoglobulin Therapy ◽  
Sivelestat Sodium Hydrate ◽  
Significant Difference ◽  
Sodium Hydrate ◽  
Sivelestat Sodium

Background: There are still no definite treatments for refractory Kawasaki disease (KD). In this pilot study, we evaluated the safety and efficacy of a new protocol consisting of sivelestat sodium hydrate (SSH) combined with additional intravenous immune globulin (IVIG) for KD patients who were resistant to initial IVIG therapy. Methods: We prospectively collected clinical data of KD patients who were resistant to initial IVIG (2g/kg for one day) and received SSH (0.2mg/kg/hour for consecutive 5 days) combined with additional IVIG (2g/kg for one day) as a second-line therapy at Chiba University hospital between December 2006 and March 2014. We defined patients who remained febrile (37.5°C or more of an axillary temperature) after 36 to 48 hours after start of initial IVIG therapy or who had recrudescent fever associated with other symptoms of Kawasaki disease as being resistant to initial IVIG. Results: Thirty five KD patients were enrolled in this study. No serious adverse effect was noted. The median total duration of fever was 8 days (range 6 to 17 days) and the incidence of coronary artery lesion (CAL) was 5.7% (2 of 35 patients). Among a total of 35 patients, 24 (69%) of them responded promptly to be afebrile 36 to 48 hours after the start of the additional IVIG with SSH. One of these 24 patients developed CAL. The other 11 (31%) failed to become afebrile 36 to 48 hours after the start of the additional IVIG with SSH therapy. Of these 11 patients, one developed CAL. Before initial IVIG, there was no difference in demographic and laboratory data except the age, body weight and % Neutrophils. However, after initial IVIG therapy, there appeared significant difference in % Neutrophils and C-reactive protein levels and both of which were higher in additional IVIG with SSH therapy non-responders than in responders. Conclusions: Additional IVIG combined with SSH for the additional treatment of KD patients who were refractory to initial IVIG therapy was safe and the incidence of CAL is acceptable considering the severity of patients in this study.

P166 SPONTANEOUS ESOPHAGEAL RUPTURE – BOERHAAVE SYNDROME

2019 ◽  
Vol 32 (Supplement_2) ◽  
Author(s):  
B  Movchan ◽  
O Usenko ◽  
A Zgonnyk ◽  
R Vynogradov
Keyword(s):  
Spontaneous Rupture ◽  
Pleural Cavity ◽  
Clinical Manifestations ◽  
Esophageal Rupture ◽  
Esophageal Stents ◽  
Spontaneous Esophageal Rupture ◽  
Timely Diagnosis ◽  
Boerhaave Syndrome ◽  
Surgical Tactics ◽  
Effective Drainage

Abstract Aim To study the most effective method of treatment in patients with spontaneous rupture of the esophagus. Background The timely diagnosis of Boerhaave syndrome presents great difficulties due to its rarity, a variety of clinical manifestations, often simulating different pathologies from other organs and are difficult to treat. Methods From 2003 to 2019 9 patients with Bourhave's syndrome were treated at the clinic, primary care was provided to 6 patients in the community. All patients were admitted to the clinic with external left-sided esophageal-pleural fistula, 1 patient had a spontaneous rupture of the esophagus in the cliniс, the defect of the esophagus wall defect was completed, which led to successful results. Results Treatment in the remaining patients was started with adequate enteral nutrition and effective drainage of the pleural cavity. As a result of the use of pleural double-lumen drainage with active sanation with antiseptics and subsequent aspiration, with the exception of feeding through the mouth in four patients, it was possible to eliminate the esophageal-pleural fistula, profuse bleeding and death of the patient. Against the background of ongoing conservative therapy in two patients, it was not possible to eliminate the esophago-pleural fistula. A left-sided thoracotomy was performed with excision of the fistula with the decortication of the lung and the extirpation of the esophagus with the formation of an esophagostomy. Subsequently, these patients underwent retrosternal colic esophagoplasty. Two patients underwent Lewis surgery with drainage of the pleural cavity. Conclusion Boerhaave syndrome has a very high mortality rate, however, with a timely diagnosis and adequate surgical tactics, it develops into the formation of an esophageal-pleural fistula. In this case, the most effective treatment is excision of the fistulous course with extirpation of the esophagus and subsequent esophagoplasty. The use of esophageal stents is possible in extremely depleted patients or in elderly patients, due to the frequent occurrence of hypergranular esophagitis. Esophageal stents should be removed as soon as possible when confidence in the elimination of the esophageal-pleural fistula occurs.

scholarly journals Sivelestat sodium hydrate treatment for refractory Kawasaki disease

2019 ◽  
Vol 61 (5) ◽  
pp. 438-443 ◽  
Author(s):  
Ryota Ebata ◽  
Kumi Yasukawa ◽  
Kazue Nagai ◽  
Yuko Saito ◽  
Kouji Higashi ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Sivelestat Sodium Hydrate ◽  
Sodium Hydrate ◽  
Sivelestat Sodium

Efficient Synthesis of Sivelestat Sodium Hydrate

2008 ◽  
Vol 38 (11) ◽  
pp. 1718-1724 ◽  
Author(s):  
G. Bijukumar ◽  
B. Maloyesh ◽  
S. S. Sampat ◽  
S. B. Bhirud ◽  
A. Rajendra
Keyword(s):  
Efficient Synthesis ◽  
Sivelestat Sodium Hydrate ◽  
Sodium Hydrate ◽  
Sivelestat Sodium

scholarly journals Intraoperative Administration of Sivelestat Sodium Hydrate (Elaspol®) for Acute Respiratory Disorder in Patient with Lung Cancer

2006 ◽  
Vol 31 (2) ◽  
pp. 165-169
Author(s):  
Tooru AKAISHI ◽  
Riichirou MORITA ◽  
Hirozou SAKAGUCHI ◽  
Satomi NAKAMURA ◽  
Hiroyuki NITANNDA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Respiratory Disorder ◽  
Sivelestat Sodium Hydrate ◽  
Sodium Hydrate ◽  
Sivelestat Sodium
Sign in / Sign up

Export Citation Format

Share Document